TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Net Income From Continuing Operations : ¥156.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is TEYI PHARMACEUTICAL GROUP CO Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. TEYI PHARMACEUTICAL GROUP CO's net income from continuing operations for the three months ended in Mar. 2024 was ¥9.2 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥156.9 Mil.

TEYI PHARMACEUTICAL GROUP CO Net Income From Continuing Operations Historical Data

The historical data trend for TEYI PHARMACEUTICAL GROUP CO's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TEYI PHARMACEUTICAL GROUP CO Net Income From Continuing Operations Chart

TEYI PHARMACEUTICAL GROUP CO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

171.71

43.82

126.92

178.20

253.18

TEYI PHARMACEUTICAL GROUP CO Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															105.47	46.65	36.36	64.69	9.16

TEYI PHARMACEUTICAL GROUP CO Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥156.9 Mil.

TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TEYI PHARMACEUTICAL GROUP CO LTD (SZSE:002728) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

Industrial Park pit, Guangdong Province, North, Taishan, CHN

Website

http://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO LTD is a pharmaceutical company. It engages in the research and development, production, and sale of proprietary Chinese medicines, and chemical drugs and raw materials in China. The main pharmaceutical preparation products cover a cough and phlegm, kidney, anti-infection, cardiovascular and digestive system. The main preparation products include Zhikebao Tablet, Jinqi Shenqi Tablet, Pharyngitis Tablet, and Erythromycin Enteric-coated Tablets.

Executives

Zhang Yong Zhao	Executives
Chen Xi Liang	Directors, Directors, and Executives
Xu Shao Hua	Securities Affairs Representative
Xu Wei Gao	Director
Xu Song Qing	Directors, executives
Liu Guang Tao	Executives
Du Yong Chun	Supervisors
Huang Yan Ling	Executives
Chen Guang Ting	Supervisors

TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Headlines

No Headlines